

A complex network diagram with numerous blue and grey nodes connected by thin lines, forming a web-like structure that fills the background of the slide.


COAIMED

•WEARVCARE•

Erika Rovini, co-founder
(erika.rovini@coaimes.com)

June 21st, 2022

PARKINSON'S DISEASE (PD)



6.1 millions



2016



> 12 millions



2050



Total Costs
13.9 B€/year



>1.400.000
patients



Total Costs
2.34 B€/year



400.000 patients

PD: CURRENT CLINICAL PRACTICE



100+ visits/month

**Visual assessment
of motor performance**

**Therapy adjustment
by phone or after months**



On average 3 visits/year

**Latent symptoms during
the visits remain undetected**

**Self-reported symptoms and
response to therapy changes**

THE UNMET NEEDS

Co-Creation Workshops

Interview

Prioritization Analysis

Neurologists, Patients, Caregivers
and Healthcare Professionals
(50+ people)



**Short time visits for
patients' complete
motor evaluation**




**Subjectivity and
variability in motor
assessment**



**Unavailable
PD patients
remote monitoring**

THE SOLUTION •WEARV•CARE•

A decision support tool for diagnosis, management and follow-up in Parkinson's disease



One solution, multiple advantages



Digitalized and objective data



Objective remote monitoring



Better use of the resources

THE SYSTEM

IoT-enabled wearables for data acquisition and processing




Proprietary AI-based algorithms for feature extraction and data analytics



Interoperable Cloud platform for data storage, visual dashboard



At hospital for diagnosis support and follow-up visits




Connected home for therapy adjustment



•WEARVCARE•

COLLABORATIONS



CLINICAL EVIDENCE

Excellent precision & Modularity(Err<5%, TRL 7)



Up to 100% accuracy in characterizing PD motor symptoms (healthy subjects vs. PD patients)

**400+ PEOPLE
ALREADY
TESTED IN
HOSPITALS**



Accurate monitoring of the motor subtle changes related to change in therapy



>80% accuracy on PD progression (mild, moderate, advanced)

COMPETITORS ANALYSIS

	WEARVARE	G WALK	Motognosis AMSA	Kinesia One
Motor Symptoms	Bradykinesia Tremor	⊘	Bradykinesia	Bradykinesia Dyskinesia Tremor
Portable	✓	✓	⊘	✓
Sensors and placement	#4 fingers; #2 wrists; #2 feet	# 1 trunk L2-S1	⊘	#1 index finger or foot
Full Body Assessment	✓	⊘	✓	⊘
No Spatial Constraints	✓	✓	⊘	✓
Exercises #	15	3	10 (lab version) 3-5 (test version)	12
Compliance to MDS-UPDRS III	72%	17%	28%	56%

AWARDS & NETWORK



Prizes & Awards

**Innovation
Award
Tuscany 2021**



StartCup Tuscany 2020



**WMF 2022
Roadshow**



Meet In Italy SUB2021



Incubation - Acceleration



UNIVERSITÀ
DEGLI STUDI
FIRENZE
SPIN-OFF APPROVATO




**Open
Accelerator**
Life Sciences
Zcube
Zambon Research Venture



Network e Partnerships



MARKET TARGET



SCALE UP



Parkinsonisms

Behaviour disorders



Cognitive decline

Clinical trials

ROADMAP, BUSINESS AND INVESTMENT MILESTONES

2014-2018




Research projects

TRL7


Clinical prevalidation
(400+ subjects tested)



Italian patents
Scientific publications



REVENUE MODEL



BY 5° YEAR:
Revenues =
7.300.000€

Net Income
= 3.900.000€

Gianmaria Mancioppi
Psychologist
PhD BioRobotics, CSO

Filippo Cavallo
Electronics Engineer
Prof. Bioengineering, Adv



Erika Rovini
Biomedical Engineer
PhD BioRobotics, CTO

Laura Fiorini
Biomedical Engineer
PhD BioRobotics, COO




Manuele Bonaccorsi,
PhD Innovation Technology,
CEO

CLINIC ADVISORY BOARD



Dr. Carlo Maremmani
Ospedale Apuane (MS)

Dr. Silvia Ramat
Parkinson Unit AOU Careggi (FI)



Dr. Paolo Bongioanni
AOU Pisana, Cisanello (PI)

Full team: >8 experts in Computer Science,
Biomedical Engineering, Product development



www.coaimed.com

management@coaimed.com

